Patents by Inventor Katherine A. Rantanen

Katherine A. Rantanen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of Ponatinib hydrochloride
    Patent number: 11072620
    Abstract: The present invention provides novel crystalline forms of Ponatinib hydrochloride. Specific crystalline forms provided by the present invention include Ponatinib hydrochloride Form APO-I, APO-III and APO-IV, each of which is obtained from acetonitrile/formic acid solutions. Additionally, Form APO-V is provided, which is obtained from concentrated hydrochloric acid.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: July 27, 2021
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Jenny L. Gerster, Annyt Bhattacharyya, Boris Gorin, Allan W. Rey
  • Crystalline form of lumacaftor
    Patent number: 10858346
    Abstract: The present invention provides a novel crystalline form of Lumacaftor, specifically Lumacaftor Form APO-I, a co-crystal of Lumacaftor and nicotinamide, compositions including this crystalline form, and processes for the preparation of this crystalline form.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: December 8, 2020
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen
  • Crystalline Forms of Ponatinib Hydrochloride
    Publication number: 20200095255
    Abstract: The present invention provides novel crystalline forms of Ponatinib hydrochloride. Specific crystalline forms provided by the present invention include Ponatinib hydrochloride Form APO-I, APO-III and APO-IV, each of which is obtained from acetonitrile/formic acid solutions. Additionally, Form APO-V is provided, which is obtained from concentrated hydrochloric acid.
    Type: Application
    Filed: June 15, 2018
    Publication date: March 26, 2020
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Jenny L. Gerster, Annyt Bhattacharyya, Boris Gorin, Allan W. Rey
  • Crystalline forms of Lesinurad
    Patent number: 10513500
    Abstract: The present invention provides novel crystalline forms of Lesinurad, pharmaceutical compositions including these crystalline forms, and their use in the treatment of hyperuricemia associated with gout. Specific crystalline forms provided by the present invention include Lesinurad Forms APO-I, a hemi-methanolate, APO-II, a hemi-ethanolate, and APO-III, a co-crystal of Lesinurad and nicotinamide.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: December 24, 2019
    Assignee: Apotex Inc.
    Inventors: Jenny L. Gerster, Katherine A. Rantanen, Allan W. Rey
  • Crystalline form of selexipag
    Patent number: 10407396
    Abstract: The present invention provides a novel crystalline form of Selexipag, Selexipag Form APO-I, which is a methanol solvate of Selexipag, compositions thereof, and the use of this crystalline form in the treatment of pulmonary arterial hypertension.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: September 10, 2019
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Annyt Bhattacharyya, Jenny L. Gerster, Allan W. Rey
  • Crystalline Forms of Lesinurad
    Publication number: 20190263760
    Abstract: The present invention provides novel crystalline forms of Lesinurad, pharmaceutical compositions including these crystalline forms, and their use in the treatment of hyperuricemia associated with gout. Specific crystalline forms provided by the present invention include Lesinurad Forms APO-I, a hemi-methanolate, APO-II, a hemi-ethanolate, and APO-III, a co-crystal of Lesinurad and nicotinamide.
    Type: Application
    Filed: November 9, 2017
    Publication date: August 29, 2019
    Inventors: Jenny L. Gerster, Katherine A. Rantanen, Allan W. Rey
  • Crystalline Form of Selexipag
    Publication number: 20190144397
    Abstract: The present invention provides a novel crystalline form of Selexipag, Selexipag Form APO-I, which is a methanol solvate of Selexipag, compositions thereof, and the use of this crystalline form in the treatment of pulmonary arterial hypertension.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 16, 2019
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Annyt Bhattacharyya, Jenny L. Gerster, Allan W. Rey
  • Crystalline Form of Lumacaftor
    Publication number: 20190112299
    Abstract: The present invention provides a novel crystalline form of Lumacaftor, specifically Lumacaftor Form APO-1, a co-crystal of Lumacaftor and nicotinamide, compositions including this crystalline form, and processes for the preparation of this crystalline form.
    Type: Application
    Filed: October 15, 2018
    Publication date: April 18, 2019
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen